The effect of beta-blocker therapy on quality of life in heart failure patients: A systematic review and meta-analysis

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 2, 2007, Pages 152-159

  Dobre, Daniela ^a   van Jaarsveld, Cornelia H M ^a   deJongste, Mike J L ^a   Ruskamp, Flora M Haaijer ^a   Ranchor, Adelita V ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Beta adrenergic antagonists; Clinical trials; Congestive heart failure; Quality of life

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CELIPROLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; PLACEBO;

BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS SOFTWARE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SELECTIVITY; EMOTIONALITY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847124803     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1234     Document Type: Review

References (35)

1. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in general population. The Rotterdam study. Eur Heart J 2001; 22: 1318-1327.
2. Cowie MR, Wood DA, Coats AJS, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83: 505-510.
3. The Task Force on heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005; 26: 1115-1140.
4. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of Beta adrenergic Blockade in chronic heart failure. A Meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation 1998; 98: 1184-1191.
5. Brophy JM, Joseph L, Rouleau JL. Beta Blockers in congestive heart failure. A Bayesian Meta-analysis. Ann Intern Med 2001: 134: 550-560.
6. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996; 334: 835-840.
7. Hobbs FDR, Kenkre JE, Roalfe AK, Davis C, Hare R, Davies MK. Impart of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J 2002; 23: 1867-1876.
8. Van Jaarsveld CHM, Sanderman R, Miedema I, Ranchor AV, Kempen GI. Changes in health-related quality of life in older patients with acute myocardial infarction or congestive heart failure: a prospective study. J Am Geriatr Soc 2001; 49: 1052-1058.
9. Rector TS, Tschumperlin LK, Kubo SH, et al. Using the living with heart failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Cardiac Failure 1995; 1: 201-206.
10. Farrell MH, Foody JM, Krumholz HM. Beta blockers in heart failure. Clinical applications. JAMA 2002; 287: 890-897.
11. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhom EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154-1161.
12. Reddy P, Dunn AB. The effect of Beta Blockers on health-related quality of life in patients with heart failure. Pharmacotherapy 2000; 20: 679-689.
13. Rector TS, Kubo SH, Cohn JN. Patients'self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure questionnaire. Heart Fail 1987; 3: 198-209.
14. Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987; 28: 220-225.
15. Verhagen AP, De Vet HCW, De Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomised clinical trials for conducting systematic reviews developed by Delphy consensus. J Clin Epidemiol 1998; 51: 1235-1241.
16. Clarke M, Oxman AD. Cochrane Reviewers Handbook 4.1.5 (updated April 2002]. In: The Cochrane Library, Issue 2, 2002. Oxford: Updated software. Updated quarterly.
17. Pollock GP, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of Bucindolol in congestive heart failure. Am J Cardiol 1990; 66: 603-607.
18. US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-2806.
19. MOCHA Investigators trial. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
20. The PRECISE Investigators trial. Double-blind, placebo-controlled study of the effects of Carvedilol in patients with moderate to severe Heart Failure. Circulation 1996; 94: 2793-2799.
21. Sanderson JE, Chan SKW, Yu CM, et al. Beta Blockers in heart failure: a comparison of a vasodilating β-Bluckers with metoprolol. Heart 1999; 79: 86-92.
22. MERIT-HF study group. Effects of controlled-released metoprolol on total mortality hospitalizations, and well-being in patients with Heart Failure. JAMA 2000; 283: 1295-1302.
23. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischaemic and dilated cardiomiopathy. Circulation 2000; 101: 378-391.
24. Metra M, Nardi M. Giubbini R, Dei Cas L. Effects of short and long-term carvedilol administration on rest and exercise hemodinamic variables, exercise capacity and clinical conditions in patients with idiopatic dilated cardiomiopathy. J Am Coll Cardiol 1994; 24: 1678-1687.
25. Packer M, Bristow MR, Cohn JN, et al. Safety and efficacy of carvedilol in severe heart failure. J Cardiac Fail 1997; 3: 173-179.
26. Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilataled cardiomiopathy: results from MDC trial. Cardiovasc Drugs Ther 1996; 10: 361-368.
27. Goldstein S, Kennedy HL, Hall C, et al. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety and effect on left ventricular ejection fraction. Am Heart J 1999; 138: 1158-1165.
28. Australia/New Zeeland Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997; 349: 375-380.
29. Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of beta blocker initiation and titration in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002; 105: 1182-1188.
30. Riegel B, Moser DK, Glaser D, et al. The Minnesota living with heart failure questionnaire: sensitivity to differences and responsiveness to intervention intensity in a clinical population. Nurse Res 2002; 51: 209-218.
31. Bulpitt CJ. Quality of life with ACEI in chronic heart failure. J Card Pharm 1999; 27: S31-S35.
32. Wiklund I, Swedberg K. Some methodological problems in analyzing quality of life data in severe congestive heart failure patients. Clin Res Pharmacoepidemiol 1991; 5: 265-273.
33. Majani G, Giardini A, Opasich C, et al. Effect of Valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan heart failure trial. J Card Fail 2005; 11: 253-259.
34. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with Vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-1816.
35. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 139-149.